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Abstract
Background: Suboptimal implantation of everolimus-eluting bioresorbable vascular scaffolds (EE- 
-BVS) leading to strut malapposition and lack of neointima coverage has been hypothesized to be linked to 
late BVS-thrombosis. Optical coherence tomography (OCT) allows assessing subtle differences in BVS- 
-healing. We aimed to link 6-months OCT-data on EE-BVS coverage and malapposition to implanta-
tion technique and clinical outcome.
Methods: Twenty-nine consecutive EE-BVS-patients were included. EE-BVS-implantation was 
guided by angiography in the first 17 patients (group 1). Vessel sizing prior to implantation and im-
plantation result was assessed by OCT in the 12 following patients (group 2). EE-BVS-implantation 
was performed in both groups with adequate lesion preparation, sizing and systematic high-pressure 
post-dilatation. All patients received 6-months invasive control including OCT-analysis and clinical 
follow-up for 2 years. 
Results: The rate of uncovered struts was group 1: 10.8 ± 10.0%; group 2: 10.6 ± 8.2%, p = 0.934. 
Target lesion failure due to BVS-thrombosis occurred in 2/17 patients at 9 and 18 months (11.8%, 
group 1), and no patients in group 2 (p = 0.218). 
Conclusions: Optical coherence tomography analysis at 6-months following EE-BVS-implantation 
finds almost 90% of struts to be covered. No difference between OCT vs. angiography-guided EE-BVS-
-implantation was observed. OCT at 6-months was not able to predict late BVS-thrombosis of EE-BVS. 
(Cardiol J 2018; 25, 4: 459–469)
Key words: optical coherence tomography, bioabsorbable vascular scaffolds,  
vascular healing
Introduction
Bioresorbable vascular scaffolds (BVS) have 
been designed to improve the limitations of con-
ventional percutaneous coronary intervention 
(PCI) with drug-eluting stents (DES), namely to 
restore vessel vasomotion and to minimize neo-
arteriosclerosis [1]. The everolimus-eluting BVS 
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(EE-BVS, Abbott Vascular, Santa Clara, USA) has 
been studied in randomized trials compared to 
EE-DES. Although initial data suggested non-
inferiority at 12-months [1], the latest registries 
and meta-analysis found an increased risk of BVS-
-thrombosis [2–5]. Suboptimal BVS-implantation 
resulting in BVS-underexpansion and malapposi-
tion was suggested to be causal [6–8]. Guidance 
by intravascular imaging in sizing and optimising 
BVS-implantation is hypothesized to solve these 
issues. A BVS specific implantation protocol in-
cluding lesion preparation, accurate vessel sizing 
and mandatory post-dilation was implemented 
after the first observations of scaffold thrombosis 
when the device first came into use in routine 
PCI in Germany back in 2013 [6, 9]. Intravascu-
lar imaging with optical coherence tomography 
(OCT) is considered to allow optimal BVS-size 
selection, strut apposition and BVS-expansion [6]. 
Recently published data found OCT to detect 
BVS-malapposition and underexpansion despite 
angiographic determined success in over 25% of 
implantations [10]. Furthermore, preliminary find-
ings of OCT-based guidance for DES-implantation 
have been shown to improve clinical outcomes 
[11]. Aside from guidance during PCI, OCT has 
become a powerful tool to evaluate DES and BVS- 
-coverage and apposition in follow-up examinations. 
Quantitative data from follow-up OCT-imaging has 
been proposed as surrogate parameters for stent 
performance linked to clinical outcome [12–16]. 
The present ALSTER-OCT ABSORB registry 
(AskLepios ST. GEoRg’s hospital-Optical Coher-
ence Tomography for follow-up of ABSORBable 
vascular scaffolds) analyzed OCT-data regarding 
BVS-coverage, neointimal thickness and apposi-
tion at 6 months following EE-BVS-implantation. 
These data were linked to implantation technique 
(angiography-guided vs. OCT-guided) and 2-year 
clinical outcome. 
Methods
Design and patient enrolment
The ALSTER-OCT ABSORB registry (Fig. 1) 
was a prospective, all-comers, single-center reg-
istry to study EE-BVS healing characteristics by 
OCT at 6 months subsequent to implantation. 
Results were stratified for implantation technique 
regarding OCT- vs. angiography-guided EE-BVS-
-implantation. The registry also tried to identify 
EE-BVS-healing patterns that would have possibly 
allowed to predict 2-year clinical outcome. Between 
01/2014 and 09/2015 surveillance angiography with 
OCT was performed in 29 patients. Patients with 
complex lesions (ostial stenosis, stenosis of the 
left main trunk, lesions ≥ 10 mm length in vessels 
≤ 3.5 mm diameter) treated with EE-BVS were eli-
gible. The lesion type assessments were performed 
according to latest ACC/AHA definitions [17]. This 
registry conforms to the guiding principles of the 
Declaration of Helsinki of 2008 and was approved 
by the local institutional review board. Written 
informed consent was obtained from all patients.
PCI and BVS implantation
All interventions and choice of antithrombotic 
therapy was performed according to current PCI 
guidelines [18]. Intravenous heparin 100 IU/kg was 
given to maintain the activated clotting time > 250 s. 
Balloon predilation was performed in all patients. 
BVS-implantation at a pressure not exceeding the 
burst pressure rate was mandatory. If post-dilation 
was performed, a non-compliant balloon was used. 
Angiographic success was defined as diameter 
stenosis < 30% with thrombolysis in myocardial 
infarction (TIMI) 3 flow by visual assessment [10]. 
After evidence of angiographic success no further 
evaluation was performed in the first 17 consecu-
tive patients (group 1: angiography-guided EE-
-BVS-implantation).
Periprocedural OCT-imaging
In patients of group 2 (OCT-guided EE-BVS-
-implantation) initial predilatation was performed 
to allow OCT-imaging of the lesions, to determine 
proximal and distal reference diameters, position of 
side branches, and further lesion characteristics. 
Further predilatation was undertaken to within 
0.5 mm of the reference vessel diameter. The 
average diameter of the target zone lumen was 
determined as reference for the BVS diameter. If 
BVS-underexpansion or malapposition was identi-
fied by angiography, further post-dilatation was 
undertaken using non-compliant balloons until 
angiographic success was achieved. A further OCT-
-analysis was performed afterwards to assess BVS-
-expansion, apposition and dissection. On the basis 
of this OCT-analysis, further BVS-optimisation was 
performed according to the following definitions: 
BVS-underexpansion was defined as minimum BVS 
area < 80% of the mean proximal and distal refer-
ence lumen areas [10]. BVS-malapposition was 
defined as incomplete BVS-apposition area deline-
ated by the abluminal side of the frame border of 
the malapposed strut and the endoluminal contour 
of the vessel wall [10, 19]. A representative case 
is presented in Figure 2.
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OCT-imaging and analysis at follow-up 
Frequency domain OCT-pullbacks were per-
formed according to guidelines and obtained with 
the Ilumien system (St. Jude Medical, Saint Paul, 
USA) [13, 14, 20, 21]. As recently described ac-
quired data was analyzed at the LightLab Imaging 
OCT-offline workstation (OCT-system software 
B.0.1, LightLab) [13, 14]. Image assessments were 
performed in every 5th cross-section. All cross-
sections were screened for quality and excluded 
from analysis if any portion of the image off of the 
screen, the image was of poor quality caused by 
residual blood, sew-up artefact, or reverberation. 
Struts located at the ostium of coronary artery 
side branches, are donated as non-apposed side-
branch struts and exclude from the analysis. 
According to previously described methods BVS 
were analyzed strut-by-strut and qualified as the 
following: Embedded covered struts: covered by 
tissue with at least 50% of the strut boundary 
below the level of the luminal surface. Protruding 
covered struts: covered by tissue and with the strut 
boundary located above the level of the luminal 
surface. Uncovered apposed struts: for those not 
covered by tissue but abutting the vessel wall and 
final uncovered and malapposed struts: for those 
not covered by tissue and not abutting the vessel 
wall. If neointimal tissue was observed, its aver-
age thickness was measured. It was measured in 
every strut between abluminal site of the strut 
core and the lumen. Since the strut thickness of 
EE-BVS is 150 μm, the strut was considered as 
covered whenever the thickness of the coverage 
was above this threshold value [19, 22, 23]. The 
strut core area was measured within the area 
of the strut. Two independent expert observers 
(blinded to the clinical and procedural charac-
teristics) did the OCT-analysis. To determine 
reproducibility, measurements of 5 randomly 
chosen patients (n = 631 struts) were repeated 
and intra- and inter-observer reproducibility were 
calculated [12].
Clinical follow-up
Target-lesion-failure was defined as a com-
posite of cardiac death, target-vessel myocardial 
infarction (MI), ischemia driven target-lesion-re-
vascularization (TLR) within 2 years [13, 14, 24]. 
Target-vessel-revascularisation (TVR) was defined 
as non-target lesion revascularization of the tar-
get vessel [13, 14, 25]. The composite of cardiac 
death, MI and ischemia driven TLR within 2 years 
was considered as major adverse cardiac events 
[13, 14, 26]. 
Figure 1. ALSTER-OCT ABSORB registry — flow chart of patients included in this prospective registry. OCT — optical 
coherence tomography; PCI — percutaneous coronary intervention.
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Statistical analysis
Continuous data were summarised as means 
and standard deviations or as medians and 25th and 
75th percentiles, as appropriate. Categorical data 
are presented as number (percentage). To account 
for the clustered nature of OCT-data, multilevel 
regression analyses on lesion level, cross-section 
level and strut level were realised [13, 14, 27]. For 
intra-group analysis within each group, an analysis 
of variance was performed. A p-value < 0.05 was 
considered to be statistically significant and all 
analyses were two-tailed. Intra-observer and inter-
observer reproducibility was assessed using the in-
traclass correlation coefficient. Statistical analysis 
was performed using GraphPad Prism, version 6 
(GraphPad Software, Inc., San Diego, CA, USA).
Results
Patient baseline characteristics 
A total of 29 patients with 31 lesions and 
40 BVSs were analyzed. Figure 1 is depicting 
the flow chart of the registry. Table 1 summarizes 
baseline patient characteristics and procedural 
details. No differences were found between the 
groups.
Figure 2. Representative images: optical coherence tomography (OCT)-guided bioresorbable vascular scaffold (BVS)-
-implantation; A. Baseline coronary angiography with occlusion of the proximal right coronary artery (RCA) resulting 
in BVS implantation; B. Angiography after implantation of a BVS (Absorb 3.0 × 28 mm, BVS is marked by white bars); 
C. Angiography at 6 months follow-up; D, E, F. OCT images at baseline after BVS implantation with perfect BVS 
apposition from distal to proximal; G, H, I. OCT images after 6 months with covered apposed BVS struts from distal 
to proximal; LAD — left anterior descending artery.
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Procedural characteristics
Lesion preparation using predilation was per-
formed in all patients. In the first 17 consecutive 
patients (19 lesions) no OCT-based pre-interven-
tional sizing was conducted. Only angiography was 
used to determine success after BVS-implantation. 
Table 1. Patient baseline characteristics and procedural data.
Characteristics All  
(n = 29)
Group 1; angiography 
guiding (n = 17)
Group 2; OCT  
guiding (n = 12)
P
Clinical features
Age [years] 56.6 ± 9.1 53.2 ± 7.3 61.4 ± 9.5 0.168
Male sex 23 (79.3%) 15 (88.2%) 8 (66.7%) 0.198
Obesity 7 (24.1%) 4 (23.5%) 3 (25.0%) 0.999
Hypertension 20 (69.0%) 11 (64.7%) 9 (75.0%) 0.694
Hyperlipidemia 16 (55.2%) 10 (58.8%) 6 (50.0%) 0.927
Diabetes mellitus type II 7 (24.1%) 2 (11.8%) 5 (41.7%) 0.092
Smoking 23 (79.3%) 15 (88.2%) 8 (66.7%) 0.198
Prior PCI 12 (41.4%) 7 (41.2%) 5 (41.7%) 0.999
Prior myocardial infarction 3 (10.3%) 1 (5.9%) 2 (16.7%) 0.553
Prior CABG 0 (0%) 0 (0%) 0 (0%) 0.999
Multivessel disease 20 (69.0%) 12 (70.6%) 8 (66.7%) 0.999
Clinical presentation at baseline
Stable angina pectoris 3 (10.3%) 3 (17.7%) 0 (0%) 0.246
Unstable angina pectoris 18 (62.1%) 9 (52.9%) 9 (75.0%) 0.273
NSTE-ACS 3 (10.3%) 2 (11.8%) 1 (8.3%) 0.999
STEMI 5 (17.2%) 3 (17.7%) 2 (16.7%) 0.999
Treatment
Number of treated lesions 33 19 14
Left anterior descending artery 19 (57.6%) 9 (47.4%) 10 (71.4%) 0.305
Left circumflex artery 6 (18.2%) 3 (15.8%) 3 (21.4%) 0.999
Right coronary artery 8 (24.2%) 7 (36.8%) 1 (7.1%) 0.098
Chronic total occlusions 3 (10.3%) 1 (5.9%) 2 (16.7%) 0.553
Lesion type A 3 (9.1%) 2 (10.5%) 1 (7.1%) 0.738
Lesion type B1 7 (21.2%) 5 (26.3%) 2 (14.3%) 0.403
Lesion type B2 10 (30.3%) 6 (31.6%) 4 (28.6%) 0.853
Lesion type C 13 (39.4%) 6 (31.6%) 7 (50%) 0.284
BVS/lesion 1 (1.1%) 1 (1.1%) 1 (1.1%) 0.200
Total BVS length [mm] 18 [18, 28] 18 [16.5, 28] 28 [18, 40] 0.013
Mean BVS diameter [mm] 2.94 ± 0.39 2.95 ± 0.44 2.92 ± 0.31 0.861
BVS under expansion 10 (30.3%) 5 (26.3%) 3 (21.4%) 0.999
Non-compliant post dilatation 12/33 (36.4%) 19 (100%) 3 (21.4%) 0.036
Drug treatment at discharge
Beta-blocker 28 (96.6%) 17 (100%) 11 (91.7%) 0.414
ACE/AT1-inhibitors 28 (96.6%) 16 (94.1%) 12 (100%) 0.999
Calcium antagonists 4 (13.8%) 2 (11.8%) 2 (16.7%) 0.999
Statins 29 (100%) 17 (100%) 12 (100%) 0.999
Diuretics 4 (13.8%) 2 (11.8%) 2 (16.7%) 0.999
Acetylsalicylic acid 29 (100%) 17 (100%) 12 (100%) 0.999
P2Y12-Inhibitors 29 (100%) 17 (100%) 12 (100%) 0.999
Values are shown as standard deviations, number (percentage) or medians and 25th and 75th percentiles, as appropriate. The lesion type  
assessments were performed according to latest ACC/AHA definitions; ACE — angiotensin converting enzyme, AT1 — angiotensin 1;  
BVS — bioresorbable-vascular-scaffolds; CABG — coronary artery bypass grafting; NSTE-ACS — non-ST elevation-acute coronary syndrome; 
OCT — optical coherence tomography; PCI — percutaneous coronary intervention; STEMI — ST-segment elevation myocardial infarction
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Angiography identified BVS-underexpansion in 
5/19 (26.3%) lesions. In one of these patients an 
additional outflow dissection was identified. As rec-
ommended by the manufacturer all 19/19 (100%) 
BVS received an optimisation using non-compliant 
balloons. After angiographic success no further 
imaging was performed. In another 12 patients 
(14 lesions) OCT-based pre-interventional lesion 
evaluation and sizing was conducted. Qualitative 
lesion evaluation found plaque rupture in 4/14 
lesions (28.6%). Concerning plaque composition 
7/14 (50%) lesions showed predominate lipid-
rich plaque, 4/14 (28.6%) fibrous plaque and 3/14 
(21.4%) fibroatheroma. Calcification was observed 
in 4/14 (28.6%) lesions. No thrombus formation 
was detected. Lesion preparation using semi-
compliant balloons was performed in all lesions. 
Angiography identified BVS-underexpansion in 
5/14 (35.7%) lesions and BVS-optimisation using 
non-compliant balloons was performed. No dissec-
tion was identified. After angiographic success an 
additional OCT-analysis was performed (Fig. 2). 
OCT detected no tissue prolapse or dissection, yet 
in 3/14 (21.4%) of lesions a BVS-underexpansion 
(1/14, 7.1%) or malapposition (2/14, 14.2%) was 
observed and further BVS-optimisation was per-
formed as described above. 
OCT-analyses
Neither at lesion level, cross-section level or 
strut level were any differences found concern-
ing coverage or apposition between the groups 
(Table 2). The qualitative assessment was highly 
reproducible and comparable to findings of other 
groups: the intra-observer and inter-observer re-
producibility (R2) were 0.86 and 0.83, respectively 
[28]. Mean neointimal area was significantly higher 
in the angio-guided group. 
Clinical follow-up
Patient clinical follow-up is shown in Table 3. 
Due to two patients (#1/#2) with BVS-thrombosis 
there were two target-lesion failure in group 1 and 
none in group 2. ST-segment elevation myocardial 
infarction (STEMI) due to BVS-thrombosis occurred 
after 9 months in patient #1 while the patient was on 
dual antiplatelet therapy (DAPT) with acetylsalicylic 
acid and clopidogrel. The patient was judged to be 
drug-compliant by the treating physician. Retro-
spectively, the OCT-analysis at 6-months showed 
no strut uncoverage or malapposition. The reason 
for BVS-thrombosis therefore remains elusive in 
this patient. The patient survived the STEMI with 
a left ventricular ejection fraction of 39%.
Patient #2 experienced a BVS-thrombosis 
with STEMI 18 months after EE-BVS-implanta-
tion. In retrospect, OCT-analysis at 6-months in 
patient #2 showed partial uncoverage and malap-
position of the EE-BVS (23.6% uncovered apposed 
struts and 1.9% uncovered malapposed struts). 
As the patient had no symptoms of angina and 
the angiographic picture was unremarkable the 
decision was made not to perform any treatment 
based on experience with current generation DES. 
DAPT was prescribed for a total of 12 months. 
18 months after EE-BVS-implantation the patient 
was readmitted with STEMI due to acute BVS-
-thrombosis. OCT at this time showed insufficient 
wall apposition in the distal part of the BVS with 
subsequent incomplete coverage with neointimal 
tissue as potential cause for the BVS-thrombosis 
(Fig. 3) [29]. The patient survived the STEMI with 
a normal ejection fraction.
Discussion
This registry describes unremarkable OCT-da-
ta at 6-month follow-up of EE-BVS treated patients. 
Scaffold struts had neointima coverage and strut 
malapposition rates similar to current generation 
DES [13]. As BVS have the same everolimus coat-
ing as EE-DES, this finding comes as no surprise. 
Yet the latest data found EE-BVS to be associated 
with a higher risk of BVS-thrombosis compared to 
EE-DES [7]. In detail the ABSORB III study found 
an increase in clinical events at 2-year with EE-BVS 
compared to EE-DES [3]. Additionally 2-year results 
from the Amsterdam Investigator-Initiated Absorb 
Strategy All-Comers Trial (AIDA) showed that the 
use of EE-BVS is associated with an increased risk of 
BVS-thrombosis and of target-vessel MI, compared 
with patients who received an EE-DES [5]. These 
findings have led to a warning letter to physicians 
by the Food and Drug Administration and a stop to 
routine implants. The future of ABSORB technology 
is therefore quite uncertain at the moment. 
The causes of BVS-thrombosis have yet to 
be fully elucidated [8]. A recent meta-analysis 
focusing on possible mechanical causes of BVS-
thrombosis utilizing intracoronary imaging found 
malapposition, incomplete lesion coverage, and un-
derdeployment are frequently observed in cases of 
early BVS-thrombosis, whereas, malapposition, late 
discontinuity and peri-strut low-intensity area are 
the predominant factors in late BVS-thrombosis [8]. 
Repeatedly improved implantation techniques 
has been hypothesized to allow for better clinical 
outcomes [7]. 
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In this series, no early BVS-thrombosis was 
observed. This finding is reassuring proving cor-
rect patient selection and improved implantation 
techniques were rolled out in Germany following 
early observations of BVS-thrombosis back in 
2012 and 2013. However, even OCT-analysis at 
6-months had previously shown subtle differences 
of stent healing and was detected even with low 
patient numbers and did not detect any substantial 
differences between OCT-guided implantation vs. 
angio-guided implantation, not even as a trend 
[13]. Even larger patient numbers are therefore 
was unlikely to reveal a different result. These 
data confirm the current implantation techniques 
including lesion preparation, sizing and mandatory 
post-dilatation with a non-compliant balloon leads 
to good short-term results. In addition, the absolute 
values of neointima coverage and strut malapposi-
tion are very similar to current generation DES at 
6-months [13]. 
Table 2. Optical coherence tomography (OCT)-findings.
Characteristics All  
(n = 29)
Group 1; angiography 
guiding (n = 17)
Group 2;OCT  
guiding (n = 12)
P
Time to follow-up [days] 201 ± 70 197 ± 82 207 ± 52 0.478
Lesion level
Analyzed lesions 31 19 14 –
Lesions with uncovered struts 28 (84.9%) 16 (84.2%) 12 (85.7%) 0.999
Lesions with ≥ 10% uncovered struts 0 [0, 1] 0 [0, 1] 0.5 [0, 1] 0.917
Lesions with ≥ 30% uncovered struts 2 (6.1%) 2 (10.5%) 0 (0%) 0.496
Lesions with ≥ 5% malapposed struts 2 (6.1%) 2 (10.5%) 0 (0%) 0.496
Cross-section level
Analyzed cross-sections 805 378 427 -
Struts analyzed per cross-section 7.2 ± 1.2 7.5 ± 1.3 6.9 ± 1.0 0.134
Cross-sections with uncovered struts 36.7 ± 28.9 33.6 ± 29.8) 41.0 ± 25.6 0.507
Cross-sections with ≥ 10%  
uncovered struts
36.7 [7.1, 55.6] 31.3 [7.0, 50.6] 43.4 [17.6, 56.8] 0.747
Cross-sections with ≥ 30%  
uncovered struts
3.5 [0, 19.8] 3.5 [0, 16.0] 6.9 [0, 21.6] 0.719
Cross-sections with ≥ 5%  
malapposed struts
0 [0, 1.9] 0 [0, 0] 0 [0, 3.0] 0.659
Mean vessel diameter [mm] 2.6 ± 0.4 2.6 ± 0.5 2.6 ± 0.3 0.854
Mean vessel area [mm2] 5.4 ± 1.8 5.5 ± 2.2 5.3 ± 1.1 0.724
Mean scaffold diameter [mm] 2.9 [2.7, 3.0] 2.9 [2.7, 3.2] 2.8 [2.6, 3.0] 0.553
Mean scaffold area [mm2] 6.3 [5.5, 7.0] 6.3 [5.7, 7.8] 6.5 [5.5, 6.9] 0.730
Mean neointimal area [mm2] 1.3 ± 0.3 1.4 ± 0.3 1.2 ± 0.2 0.032
Mean area of malapposition [mm2] 0 [0, 0] 0 [0, 0] 0 [0, 0.5] 0.147
Strut level
Analyzed struts 5837 2790 3047 –
Struts analyzed/patient 160 [111, 199] 154 [107, 179] 171 [121, 250] 0.127
Covered embedded struts 76.9 ± 14.9 77.8 ± 17.4 75.8 ± 11.1 0.701
Covered protruding struts 12.0 ± 9.5 10.8 ± 10.2 13.5 ± 8.5 0.655
Uncovered apposed struts 10.7 ± 9.2 10.8 ± 10.0 10.6 ± 8.2 0.934
Uncovered malapposed struts 0 [0, 0] 0 [0, 0] 0 [0, 0] 0.779
Neointimal thickness [μm] 95.7 [81, 111] 102.2 [92, 114] 82.3 [76, 95] 0.176
Strut core area [mm2] 0.04 [0.03, 0.04] 0.04 [0.03, 0.04] 0.04 [0.03, 0.04] 0.999
Non apposed side branch struts 86 36 50 -
Excluded struts 1129 550 579 -
Values are standard deviations, number (percentage) or medians and 25th and 75th percentiles, as appropriate
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Surprisingly OCT at 6-months was unable to 
define patients at risk for BVS-thrombosis based 
on the characteristics of strut malapposition and/ 
/or neointima growth. The two patients that de-
veloped BVS-thrombosis at 9 and 18-months had 
BVS-healing patterns not much different from the 
rest of the cohort. Discontinuation of DAPT is an 
important cause of BVS-thrombosis [7], yet the 
patient was deemed to be compliant and DAPT 
can be stopped as early as 3-months after DES- 
-implantation without any increased risk of stent-
thrombosis. 
The OCT-analyses of the 2 cases of BVS-
-thrombosis were inconsistent. While the first pa-
tient had a really unremarkable finding of BVS-heal-
ing with almost complete coverage at 6-months, 
the second patient had malapposed struts partially 
covered with neointima at the distal end due to an 
enlargement of the vessel at that particular site. 
This is seen regularly with current generation DES 
and is left untreated without consequences [13]. 
Apparently BVS is less forgiving in this instance 
yet treatment options are limited if the vessel has 
various diameters like in this case; the only avail-
able option is to prolong DAPT beyond 1 year and 
most likely until the BVS is completely resorbed 
which would result in DAPT to be necessary for 
3 years. A recent study found no case of very late 
BVS-thrombosis in patients who continued on 
DAPT for > 18 months [30]. Although prolongation 
of DAPT may prevent BVS-thrombosis, the rate of 
bleeding events are a matter of concern. 
So apparently, improved implantation tech-
niques are unlikely to resolve the issues around 
BVS late clinical events. Another speculation would 
be that the BVS-polylactite material may have a late 
prothrombotic or platelet activation property dur-
ing resorbing which is not sufficiently understood 
in the human environment. While there are no such 
data available the observation from this small co-
hort, as well as from the recently presented AIDA 
trial which had a much larger cohort of patients, it 
was also unable to link implantation technique or 
any other variable to late BVS-thrombosis suggests 
other factors could be involved than those currently 
under discussion [5].
The 3-year data of ABSORB-China and 
ABSORB-Japan found no increased rate of BVS-
-thrombosis. An optimal implantation technique 
was suggested to be responsible for these findings 
[31, 32]. Yet the AIDA trial did not support this hy-
pothesis [5]. Aggressive post-dilation may trigger 
endothelial growth. While all angiography-guided 
BVS were postdilated, the OCT-guided group only 
received postdilatation in 21.4% of cases. In this 
context it is quite a striking follow-up, OCT found 
increased neointimal growth reaching a similar 
thickness compared to data observed with DES in 
the angio-guided group which is possibly linked to 
aggressive post-dilation [13]. 
Table 3. Clinical follow-up.
Two-year clinical follow-up All  
(n = 29)
Group 1; angiography  
guiding (n = 17)
Group 2; OCT  
guiding (n = 12)
P
Major adverse cardiac event 2 (6.9%) 2 (11.8%) 0 (0%) 0.218
All cause death 0 (0%) 0 (0%) 0 (0%) 0.999
Unstable angina pectoris 3 (10.3%) 2 (11.8%) 1 (8.3%) 0.765
Non-ST elevation-acute  
coronary syndrome
0 (0%) 0 (0%) 0 (0%) 0.999
ST elevation myocardial infarction 2 (6.9%) 2 (11.8%) 0 (0%) 0.218
Target-vessel-failure 0 (0%) 0 (0%) 0 (0%) 0.999
Target-vessel-revascularization 0 (0%) 0 (0%) 0 (0%) 0.999
Target-lesion-failure 2 (6.9%) 2 (11.8%) 0 (0%) 0.218
Target-lesion-revascularization 2 (6.9%) 2 (11.8%) 0 (0%) 0.218
In-stent restenosis 0 (0%) 0 (0%) 0 (0%) 0.999
Scaffold-thrombosis 2 (6.9%) 2 (11.8%) 0 (0%) 0.218
Major bleeding event 0 (0%) 0 (0%) 0 (0%) 0.999
Minor bleeding event 1 (3.4%) 1 (5.9%) 0 (0%) 0.393
Cerebrovascular event 1 (3.4%) 1 (5.9%) 0 (0%) 0.393
The data are presented as number of events (n) and percentage of total number (%).
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Figure 3. ST-elevation myocardial infarction (STEMI) due to bioresorbable vascular scaffold (BVS)-thrombosis: 
Angiographies and optical coherence tomography (OCT)-images; A. Baseline coronary angiography with significant 
stenosis of the proximal right coronary artery (RCA) resulting in BVS implantation; B. Angiography after implantation 
of a BVS (Absorb 3.5 × 28 mm, BVS is marked by white bars); C. Angiography at 6 months follow-up; D. OCT of the 
distal BVS at 6 months follow-up. Please note the insufficient wall apposition and coverage (white arrows); E. Angio-
graphy showing acute BVS-thrombosis of the RCA 18 months after implantation (scaffold area is marked by white 
bars); F. Angiography after reopening of RCA via thrombus aspiration; G. OCT of the distal BVS at the time of BVS 
thrombosis showing thrombus material attached to the struts and malapposition and coverage as a potential reason 
for thrombosis (white arrows marks malapposed uncovered struts, red arrow shows thrombus material attached to 
the struts); H. OCT of the distal BVS with thrombus material which is narrowing the RCA. 
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Lesion preparation and post-dilatation with 
non-compliant balloons has been suggested to im-
prove EE-BVS implantation results [7]. Mandatory 
post-dilatation was thought to improve implantation 
outcomes; the OCT-guided data presented here 
find OCT-guided intervention to lead to comparably 
good results. Vice versa, angio-guided implantation 
with mandator post-dilatation has similar results 
than OCT-guided BVS-implantation. Yet this opti-
mization appears not to prevent BVS-thrombosis. 
The reasons for this are unclear and apparently 
needs to be identified prior to further routine use 
of EE-BVS. The fact that BVS-thrombosis did occur 
despite BVS-coverage similar to EE-DES leads to 
the hypothesis that either strut thickness or the 
BVS-material could be the issue leading to these 
late events. The issue that the underlying mate-
rial and resorption may activate platelet adhesion 
should be investigated and addressed including 
other materials like magnesium, which should be 
further studied. 
Limitations of the study
The fact that no randomization was performed 
is limiting in the conclusions reached. A further 
limitation is the limited number of patients and 
the differring sample size of the two groups. The 
number of patients is certainly too small to draw 
definitive conclusions about clinical outcomes, yet 
OCT-assessment of BVS-apposition and coverage 
correlates to clinical outcomes [12–15]. 
Conclusions 
This registry found almost 90% of BVS-struts 
to be covered with neointima at 6 months. Both an-
giography- and OCT-guided EE-BVS-implantation 
had favourable 6-month results based on OCT-data. 
Yet OCT-analyses at 6-months were not able to 
predict late clinical events as there were in this 
study with 2 BVS-thrombosis occurring 9 and 
18 months following BVS-implantation. 
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